Clinical Outcomes Solutions Partners with Genesis Research: A New Era in Life Sciences
In a move that promises to redefine the landscape of patient-centered research in life sciences, Clinical Outcomes Solutions (COS) has officially announced its innovative partnership with Genesis Research.
Both powerhouses in their respective domains, COS has been a torchbearer since 2013, pioneering in the assimilation and communication of the patient voice. Their qualitative and quantitative research methodologies have made strides in Clinical Outcomes Assessments, ensuring that drug development is driven by real patient needs.
Genesis Research, with its global reach, has been at the helm of Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR). Their tech-enabled solutions have provided invaluable insights to pharmaceutical, biotech, and medical device clients, guiding them through the intricate phases of the product lifecycle.
But why is this collaboration groundbreaking?
The regulatory arena concerning RWE is dynamic, and the fusion of COS's expertise in Clinical Outcomes Assessment with Genesis Research's prowess in evidence-based research ensures both firms remain at the cutting edge. This symbiosis promises to usher in a new era of research that prioritizes the needs of clients, payers, and regulators alike.
Stacie Hudgens, the visionary CEO of COS, expressed her excitement:
“Evidence generation of patient-centered outcomes begins with prospective and clinical studies and expands through real-world treatment experience and symptom management. This partnership and the additional Oncology Outcomes partners provide Life Sciences Companies (LSCs) with vast evidence to support new anti-cancer therapy clinical development programs.”
Stacie Hudgens
CEO of COS
Echoing Hudgens' sentiments, Tara Symonds, Chief Science Officer at COS, elaborated on the importance of real-world studies:
"These studies, pivotal in capturing patient-centric effectiveness data, demand meticulous design and execution. Our combined expertise sets a gold standard for Life Sciences Companies, especially with the escalating demand for such data by regulators and payers."
Tara Symonds
CSO of COS
On the other side of the partnership, Chris Pashos from Genesis Research's Board of Directors highlighted:
“Regulatory bodies worldwide have made RWE and COA central to considering new therapies developed by LSCs. This partnership offers LSCs the combined capabilities of leaders in these areas. Together the partnership can ensure that LSCs develop and execute timely strategies that will meet the evidentiary requirements of regulators.”
Chris Pashos
Board of Directors, Genesis Research
Susan Oliveria, the Chief Scientific Officer at Genesis Research, summed up the essence of the collaboration:
“RWE and COA are now recognized as central to developing and commercializing new therapies. The partnership allows LSCs to successfully plan and execute an integrated evidence generation plan that will be patient-centric and meet the needs of regulators, payers, medical professionals, and the patient community.”
Susan Oliveria
CSO of Genesis Research
To delve deeper into this groundbreaking partnership, or to request a meeting, click here.
In the ever-evolving realm of life sciences, collaborations like these push the boundaries of what's possible and ensure that patient voices remain at the heart of every scientific endeavor. The partnership of COS and Genesis Research is a beacon of hope for a brighter, more patient-centric future in drug development and beyond.